Antibody-based concepts for multipurpose prevention technologies

Antiviral Research

Volumn 100, Issue 1, 2013, Pages

  Whaley, Kevin J ^a   Zeitlin, Larry ^a  

^a Mapp Biopharmaceutical Inc   (United States)

Author keywords

Herpes simplex virus; Human immunodeficiency virus; Multi antibody; Multipurpose prevention technologies; Sperm

Indexed keywords

ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; SPERM ANTIBODY; VACCINE;

ANTIBODY DEPENDENT ENHANCEMENT; DRUG MANUFACTURE; HERPES SIMPLEX VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; NONHUMAN; PRIORITY JOURNAL; REVIEW;

HUMAN IMMUNODEFICIENCY VIRUS; SIMPLEXVIRUS;

HERPES SIMPLEX VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; MULTI-ANTIBODY; MULTIPURPOSE PREVENTION TECHNOLOGIES; SPERM;

ANIMALS; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; HERPES SIMPLEX; HIV INFECTIONS; HIV-1; HUMANS; SIMPLEXVIRUS;

EID: 84890879718     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2013.09.027     Document Type: Review

References (73)

1. Abdel-Motal U., Sarkis P.T.N., Han T., Pudney J., Anderson D.J., Zhu Q., Marasco W.A. Anti-gp120 minibody gene transfer to female genitial epithelial cells protect against HIV-1 virus challenge in vitro. PLoS One 2011, 6:1-6.
2. Adamiak B., Trybala E., Mardberg K., Johansson M., Liljeqvist J.-A., Olofsson S., Grabowska A., Bienkowska-Szewcsyk K., Bergstrom T. Human antibodies to herpes virus type 1 glycoprotein C are neutralizing and target the heparin sulfate-binding domain. Virology 2010, 400:197-206.
3. Anderson D.J. Finally, a macaque model for cell-associated SIV/HIV vaginal transmission. J. Infect. Dis. 2010, 202:333-336.
4. Anderson D.J., Politch J.A., Nadolski A.M., Blaskewicz C.D., Pudney J., Mayer K.H. Targeting Trojan Horse leukocytes for HIV prevention. AIDS 2010, 24:163-187.
5. Awasthi S., Lubinski J.M., Shaw C.E., Barrett S.M., Cai M., Wang F., Betts M., Kingsley S., DiStefano D.J., Balliet J.W., Flynn J.A., Casimiro D.R., Bryan J.T., Friedman H.M. Immunization with a vaccine combining Herpes Simplex Virus 2 (HSV-2) glycoprotein C (gC) and gD subunits improves the protection of dorsal root ganglia in mice and reduces the frequency of recurrent vaginal shedding of HSV-2 DNA in guinea pigs compared to immunization with gD alone. J. Virol. 2011, 85:10472-10486.
6. Bakker A.B., Python C., Kissling C.J., Pandya P., Marissen W.E., Brink M.F., Lagerwerf F., Worst S., van Corven E., Kostense S., Hartmann K., Weverling G.J., Uytdehaag F., Herzog C., Briggs D.J., Rupprecht C.E., Grimaldi R., Goudsmit J. First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity. Vaccine 2008, 26:5922-5927.
7. Balazs A.B., Chen J., Hong C.M., Rao D.S., Yang L., Baltimore D. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 2011, 10.1038/nature10660.
8. Beltramello M., et al. The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 2010, 8:271-283.
9. Burton D.R., Hessell A.J., Keele B.F., Klasse P.J., Ketas T.A., Moldt B., Dunlop D.C., Poignard P., Doyle L.A., Cavacini L., Veazey R.S., Moore J.P. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHI challenge of macaquest compared with a strongl neutralizing antibody. PNAS 2011, 108:11181-11186.
10. Castle P.E., Whaley K.J., Hoen T.E., Moench T.R., Cone R.A. Contraceptive effect of sperm-agglutinating monoclonal antibodies in rabbits. Biol. Repro. 1997, 56:153-159.
11. CB-UPMC, Center for Biosecurity of UPMC. Next-Generation Monoclonal Antibodies: Challenges and Opportunities. Final Report-February 2013.
12. Chargelegue D., Drake P.M.W., Pbregon P., Prada A., Fairweather N., Ma J.K.-C. Highly immunogenic and protective recombinant vaccine candidate expressed in transgenic plants. Inf. Immun. 2005, 73:5915-5922.
13. Cole J.G., Jerse A.E. Functional characterization of antibodies against Neisseria gonorrhoeae. PLoS One 2009, 4:1-11.
14. Cone R.A., Whaley K.J. Monoclonal antibodies for reproductive health: Preventing sexual transmission of disease and pregnancy with topically applied antibodies. Am. J. Reprod. Immunol. 1994, 32:114-131.
15. Dall'Acqua W.F., Kiener P.A., Wu H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J. Biol. Chem. 2006, 281:23514-23524.
16. De Logu A., Williamson R.A., Rozenshteyn R., Ramiro-Ibañez F., Simpson C.D., Burton D.R., Sanna P.P. Characterization of a type-common human recombinant monoclonal antibody to herpes simplex virus with high therapeutic potential. J. Clin. Microbiol. 1998, 36:3198-3204.
17. 162P3 in cynomolgus macaques. PLoS Path. 2012, 12:e1003071.
18. Diekman A.B., Norton E.J., Klotz K.L., Westbrook V.A., Shibahara H., Naaby-Hansen S., Flickinger C.J., Herr J.C. N-linked glycan of a sperm CD52 glycoform associated with human infertility. FASEB J. 1999, 13:1303-1313.
19. Diekman A.B., Norton E.J., Westbrook V.A., Klotz K.L., Naaby-Hansen S., Herr J.C. Anti-sperm antibodies form infertile patients and their cognate sperm antigens: a review. Identity between SAGA-1, the H6-3C4 antigen, and CD52. AJRI 2000, 43:134-143.
20. Farid S.S. Process economics of industrial monoclonal antibody manufacture. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2007, 848:8-18.
21. FDA, 2010, Guidance for Industry; Codevelopment of two or more unmarketed investigational drugs for use in combination. CDER.
22. FDA., 1997 Guidance for Industry; For the evaluation of combination vaccines for preventable diseases: production, testing, and clinical studies. CBER.
23. Frandsen T.P., Naested H., Rasmussen S.K., Hauptig P., Wiberg F.C., Rasmussen L.K., Jensen A.M., Persson P., Wikén M., Engström A., Jiang Y., Thorpe S.J., Förberg C., Tolstrup A.B. Consistent manufacturing and quality control of a highly complex recombinant polyclonal antibody product for human therapeutic use. Biotechnol. Bioeng. 2011, 108:2171-2181.
24. Giritch A., Marillonnet S., Engler C., van Eldik G., Botterman J., Klimyuk V., Gleba Y. Rapid high-yield expression of full-size IgG antibodies in plants coinfected with noncompeting viral vectors. PNAS 2006, 103:14701-14706.
25. Harrison P.F., Hemmerling A., Romano J., Whaley K.J., Young Holt B. Developing multipurpose reproductive health technologies: an integrated strategy. AIDS Res. Treat. 2013, 2013:790154. 10.1155/2013/790154. Epub 2013 Feb 28.
26. Hessell A.J., Poignard P., Hunter M., Hangartner L., Tehrani D.M., Bleker W.M., Parren P.W.H.I., Marx P.A., Burton D.R. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat. Med. 2009, 8:951-954.
27. Hessell A.J., Rakasz E.G., Tehrani D.M., Huber M., Weusgrau K.L., Landucci G., Forthal D.N., Kof W.C., Poignard P., Watkins D.I., Burton D.R. Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosla challenge by simian-human immunodeficiency virus SHIV Ba-L. J. Virol. 2010, 84:1302-1313.
28. Hiatt A., Zeitlin L., Whaley K.J. Multi-antibody strategies for HIV. Clin. Dev. Immunol. 2013, 2013:632893. 10.1155/2013/632893. Epub 2013 Jun 6.
29. Hinton P.R., Xiong J.M., Johlfs M.G., Tang M.T., Keller S., Tsurushita N. An engineered human IgG1 antibody with longer serum half-life. J. Immunol. 2006, 176:346-356.
30. Hook, L.M., Friedman, H.M. 2007. Subversion of innate and adaptive immunity: immune evasion from antibody and complement. In: Arvin, A., Capadelli-Fiume, G., Mocarski, E., et al., (eds) Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis. Cambridge: Cabridge University Press; 2007.
31. Huang J., Ofek G., Laub L., Louder M.K., Doria-Rose N.A., Longo N.S., Imamichi H., Bailer R.T., Chakrabarti B., Sharma S.K., Alam S.M., Want T., Yang Y., Zhang B., Migueles S.A., Wyatt R., Haynes B.F., Kwong P.D., Mascola J.R., Connors M. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 2012, 491:406-412.
32. Hur E.M., Patel S.N., Shimizu S., Rao D.S., Gnanapragasam P.N.P., An D.S., Yang L., Baltimore D. Inhibitory effect of HIV-specific neutralizing IgA on mucosla transmission of HIV in humanized mice. Blood 2012, 120:4571-4582.
33. Ismael G., Hegg R., Muehlbauer S., Heinzmann D.L., Kim S.-B., Pienkowski T., Lichinster M., Semiglazov V., Melichar B., Jackisch C. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical state I-III breast cancer (HannaH study): a phase 3, open-label, multicenter, randomized trial. Lancet Oncol. 2012, 13:869-878.
34. Kelley B. Very large scale monoclonal antibody purification: the case for conventional unit operations. Biotechnol. Prog. 2007, 23:995-1008.
35. Klein F., Halper-Stromberg A., Horwitz J.A., Gruell H., Scheid J.F., Bournazos S., Mouquet H., Spatz L.A., Diskin R., Abadir A., Zang T., Dorner M., Billerbeck E., Labitt R.N., Gaebler C., Marcovecchio P.M., Incesu R.-B., Eisenreich T.R., Bieniasz P.D., Seaman M.S., Bjorkman P.J., Ravetch J.V., Ploss A., Nussenzweig M.C. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 2012, 492:118-122.
36. Kouokam J.C., Huskens D., Schols D., Johannemann A., Riedell S.K., Walter W., Walker J.M., Matoba N., O'Keefe B.R., Palme K.E. Investigation of griffithsin's intaeractions with human cells confirms its outstanding safety and efficacy profile as a microbicide candidate. PLoS One 2011, 6:e22635.
37. Krawczyk A., Krauss J., Eis-Hubinger A.M., Daumer M.P., Schwarzenbacker R., Dittmer U., Schneweis K.E., Jager D., Roggendorf M., Arndt M.A.E. Impact of valency of a glycoprotein B-specific monoclonal antibody on neutralization of herpes simplex virus. J. Virol. 2011, 85:1793-1803.
38. Lagenaur L.A., Sanders-Beer B.E., Brichacek B., Pal R., Liu X., Liu Y., Yu R., Venson D., Lee P.P., Hamer D.H. Prevention of vagina SHIV transmission in macaques by a live recombinant Lactobacillus. Mucosal Immunol. 2011, 4:648-657.
39. Lagenaur L.A., Villarroel V.A., Bundoc V., Dey B., Berger E.A. SCD4-17b bifunctional protein; Extremely broad and potent neutralization of HIV-1 Env pseudotyped viruses from genetically diverse primary isolates. Retrovirology 2010, 7:11.
40. Liao, H-X., Lynch, R., Zhou, T., Gao, F., Alam, S. M., Boyd, S. D., Fire, A. Z., Roskin, K. M., Schramm, C. A., Zhang, Z., Zhu, J., Shapiro, L., NISC Comparative Sequencing Program, Mullikin, J. C., Gnanakaran, S., Hraber, P., Wiehe, K., Kelsoe, G., Yang, G., Xia, S-M., Montefirori, D. C., Parks, R., Lloyd, K. E., Scearce, R. M., Soderberg, K. A., Cohen, M., Kamanga, G., Louder, M. K., Tran, L. M., Chen, Y., Cai, F., Chen, S., Moquin, S., Du, X., Joyce, M. G., Srivaatsan, S., Zhang, B., Zheng, A., Shaw, G. M., Hahn, B. H., Kepler, T. B., Korber, B. T. M., Kwong, P., Mascola, J. R., Haynes, B. F., 2013 Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 496, 469-76.
41. Liau A., Stupiansky N.W., Rosenthal S.L., Zimet G.D. Health beliefs and vaccine costs regarding human papillomavirus (HPV) vaccination among a U.S. national sample of adult women. Prev. Med. 2012, 54:277-279.
42. Lu L., Palaniyandi S., Zeng R., Bai Y., Liu X., Wang Y., Pauza C.D., Roopenian D.C., Zhu X. A neonatal Fc receptor-targeted mucosal vaccine strategy effectively induces HIV-1 antigen-specific immunity to genital infection. J. Virol. 2011, 85:10542-10553.
43. Mader A., Kunert R. Evaluation of the potency of the anti-idiotypic antibody Ab2/3H6 mimicking gp41 as an HIV-1 vaccine in a rabbit prime/boost study. PLoS One 2012, 7:e39063.
44. Mascola J.R., Lewis M.G., Stiegler G., Harris D., VanCott T.C., Hayes D., Louder M.K., Brown C.R., Sapan C.V., Frankel S.S., Yu L., Robb M.L., Katinger H., Birx D.L. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J. Virol. 1999, 73:4009-4018.
45. Moog, C., Dereuddre-Bosquet, N., Teillaud, J-L., Biedma, M., Holl, V., Vanham, G., Heyndrickz, L., Van Dorsselaer, A., Katinger, D., Vcelar, B., Zolla-Pazner, S., Mangeot, I., Kelly, C., Shattock, R., LeGrand, R. 2013. Protective effect of vaginal application of neutralizing and non-neutralizing inhibitory antibodies against vaginal SHIV challenge in macaques. Mucosal Immunol. 2013 Apr 17. doi: 10.1038/mi.2013.23.
46. Morris, G., Chindove, S., Woodhall, S., Wiggins, R., Vcelar, B., Lacey, C., 2010. A prospective randomized double blind placebo-controlled phase 1 pharmokinetic and safety study of a a vaginal microbicide gel containing three potent broadly neutralizing monoclonal antibodies (2F5, 2G12, 4E10) (MabGel). Microbicides 2010 (Pittsburgh, PA) abstract LB1.
47. Nayak, S., McKenzie, R., Fuchs, E., Jurao, R., Goodwin, J., Zimmerman, E., An, A., Hendrix, C., Liu, Q., Ma, J., Ahene, A., Espinosa, Y., Griffiss, J., Zenilman, J. 2013. Safety and Pharmacokinetics of a Novel Co-Mixture of Three Monoclonal Antibodies against Botulism in Healthy Subjects. ASM Biodefense meeting Feb 25-27 Washington DC.
48. Olmsted S.S., Padgett J.L., Yudin A.I., Whaley K.J., Moench T.R., Cone R.A. Diffusion of macromolecules and virus-like particles in human cervical mucus. Biophys. J. 2001, 81:1930-1937.
49. Phalipon A., Cardona A., Kraehenbuhl J.P., Edelman L., Sansonett P.J., Corthesy B. Secretory component: a new role in secretory IgA-mediated immune exclusion. Immunity 2002, 17:107-115.
50. Rank R.G., Whittum-Hudson J.A. Protective immunity to chlamydial genital infection: evidence from animal studies. J. Inf. Dis. 2010, 201:S168-S177.
51. Sagar M., Akiyama H., Etemad B., Ramirez N., Freitas I., Gummuluru S. Transmembrane domain membrane proximal external region bu not surface unit-directed broadly neutralizing HIV-1 antibodies can restrict dendritic cell-mediated HIV-1 trans-infection. J. Inf. Dis. 2012, 205:1248-1257.
52. Sallé B., Brochard P., Bourry O., Mannioui A., Andrieu T., Prevot S., Dejucq-Rainsford N., Dereuddre-Bosquet N., Le Grand R. Infection of macaques after vaginal exposure to cell-associated simian immunodeficiency virus. J. Infect. Dis. 2010, 202:337-344.
53. Sherwood J.K., Zeitlin L., Whaley K.J., Cone R.A., Saltzman M. Controlled release of antibodies for long-term topical passive immunoprotection of female mice against genital herpes. Nat. Biotech. 1996, 14:468-471.
54. Stasi R. Rozrolimupab, symphobodies against rhesus D, for the potential prevention of hemolytic disease of the newborn and the treatment of idiopathic thrombocytopenic purpura. Curr. Opin. Mol. Ther. 2010, 12(6):734-740.
55. Strasser R., Stadlmann J., Schahs M., Stiegler G., Quendler H., Mach L., Glossl J., Weterings K., Pabst M., Steinkellner H. Generation of glyco-engineered Nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human-like N-glycan structure. Plant Biotechnol. J. 2008, 6:392-402.
56. Strasser R., Castilho A., Stadlmann J., Kunert R., Quendler H., Gattinger P., Jez J., Rademacher T., Altmann F., Mach L., Steinkellner H. Improved virus neutralization by plant-produced anti-HIV antibodies with a homogeneous beta1,4-galactosylated N-glycan profile. J. Biol. Chem. 2009, 284:20479-20485.
57. Stupiansky N.W., Rosentha S.L., Wiehe S.E., Zimet G.D. Human papillomavirus vaccine acceptability among a national sample of adult women in the USA. Sex Heath 2010, 7:304-309.
58. Veazey R.S., Shattock R.J., Pope M., Kirijan J.C., Jones J., Hu Q., Ketas T., Marx P.A., Klasse P.J., Burton D.R., Moore J.P. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat. Med. 2003, 9:343-346.
59. Veselinovic M., Neff C.P., Mulder L.R., Akkina R. Topical gel formulation of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 confers protection against HIV-1 vaginal challenge in humanized mouse model. Virology 2012, 432:505-510.
60. Vose J.R. 1999. Combination Vaccines: Regulatory Considerations for Developers. In: Combination Vaccines: From Clinical Research to Approval. In: Ellis RW (ed.) Humana Press, Totowa NJ pp. 213-231.
61. Walker L.M., Huber M., Doores K.J., Falkowska E., Pejchal R., Juien J.-P., Wan S.-K., Ramos A., Chan-Hui P.-Y., Moyle M., Mitcham J.L., Hammond P.W., Olsen O.A., Phung P., Fling S., Wong C.-H., Phogat S., Wrin T., Simek M.D., Koff W.C., Wilson I.A., Burton D.R., Poignard P. Broadly neutralization coverage of multiple highly potent antibodies. Nature 2011, 477:466-470.
62. Walker L.M., Burton D.R. Rational antibody-based HIV vaccine design: current approaches and future directions. Curr. Opin. Immunol. 2010, 22:358-366.
63. Warne N.W. Development of high concentration protein biopharmaceuticals: the use of platform approaches in formulation development. Eur. J. Pharm. Biopharm. 2011, 78:208-212.
64. Watkin J.D., Sholukh A.M., Mukhtar M.M., Siddappa N.B., Lakhashe S.M., Kim M., Reinherz E.L., Gupta S., Forthal D.N., Sattentau Q.J., Villinger F., Corti D., Ruprecht R.M. Anti-HIV IgA isotypes: differential virion capture and inhibition of transcytosis are linked to prevention of mucosal R5 SHI transmission. AIDS 2013, 27:F13-F20.
65. Whaley K.J., Hiatt A., Zeitlin L. Emerging antibody products and Nicotiana manufacturing. Human Vaccine 2011, 7:349-356.
66. Whaley, K.J., Morton, J., Hume, S., Hiatt, E., Bratcher, B., Klimyuk, V., Hiatt, A., Pauly, M., Zeitlin, L., 2012. Emerging antibody-based products. Curr. Topics Microbio. Immun. [Epub ahead of print].
67. WHO Laboratory Manual for the Examination of Human Semen and Sperm-Cervical Mucus Interaction 1992, Cambridge Press. 3rd ed.
68. Ye L., Zeng R., Bai Y., Roopenian D.C., Zhu X. Efficient mucosal delivery of vaccine using the FcRn-mediated IgG transfer pathway. Nat. Biotech. 2011, 29:158-163.
69. Zalevsky J., Chamberlain A.K., Horton H.M., Karki S., Leung I.W.L., Sproule T.J., Lazar G.A., Roopenian D.C., Desjarlais J.R. Enhanced antibody half-life improves in vivo activity. Nat. Biotech. 2010, 28:157-159.
70. Zeitlin L., Whaley K.J., Sanna P.P., Moench T.R., Bastidas R., De Logu A., Williamson R.A., Burton D.R., Cone R.A. Topically applied human recombinant monoclonal IgG1 antibody and its Fab and F(ab')2 fragments protect mice from vaginal transmission of HSV-2. Virology 1996, 225:213-215.
71. Zeitlin L., Olmsted S.S., Co M.S., Martinell B.J., Paradkar V.M., et al. A humanized monoclonal antibody produced in transgenic plants for immunoprotection of the vagina against genital herpes. Nat. Biotechnol. 1998, 16:1361-1364.
72. Zeitlin L., Whaley K.J., Hegarty T.A., Moench T.R., Cone R.A. Tests of vaginal microbicides in the mouse genital herpes model. Contraception 1997, 56:329-335.
73. Zhu W., Chen C.-J., Thomas C.E., Anderson J.E., Jerse A.E., Sparling P.F. Vaccines for gonorrhea: can we rise to the challenge?. Front. Microbio. 2011, 12:1-13.